• Explore /
  • Poster
  • / Phase 1b/2 study of enzalutamide (ENZ) with LY3023414 (LY) or placebo (PL) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) after progression on abiraterone.

Phase 1b/2 study of enzalutamide (ENZ) with LY3023414 (LY) or placebo (PL) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) after progression on abiraterone.

Abstract Poster

Authors

null

Christopher Sweeney

Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA

Christopher Sweeney , Ivor John Percent , Sunil Babu , Jennifer Cultrera , Bryan Allyn Mehlhaff , Oscar B. Goodman Jr., David Morris , Ian D. Schnadig , Costantine Albany , Neal D. Shore , Paul R Sieber , Susan Guba , Minmin Wang , Suhyun Kang , Volker Wacheck , Gregory P Donoho , Anna M. Szpurka , Sophie Callies , Boris K. Lin , Johanna C. Bendell

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Genitourinary (Prostate) Cancer

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Prostate Cancer - Advanced Disease

Clinical Trial Registration Number

NCT02407054

Citation

J Clin Oncol 37, 2019 (suppl; abstr 5009)

DOI

10.1200/JCO.2019.37.15_suppl.5009

Abstract #

5009

Poster Bd #

121

Abstract Disclosures

Similar Posters

First Author: Benedito A. Carneiro

First Author: Edwin M. Posadas

First Author: Daniel P. Petrylak

First Author: Syed A. Hussain